Several large-scale CV outcome trials of SGLT2 inhibitors in individuals with T2D (Table 1) consistently showed an early reduction in incident HF in approximately 85–90% of patients without HF at baseline, and the effect was independent of glucose lowering per se [11,12,13]. Here, SLC5A2 is linked to type 2 diabetes mellitus.